News Releases

February 9, 2017

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections  VANCOUVER, BC – February 9, 2017 – RepliCel Life... Read full article

February 7, 2017

Replicel Life Sciences Inc. Announces Brokered Private Placement
VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine... Read full article

February 3, 2017

RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (“RepliCel” or the “Company”) is pleased to announce the... Read full article

January 4, 2017

RepliCel CEO Provides 2017 Forecast
After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion of medical device prototypes VANCOUVER, BC – January 5,... Read full article